Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

The Comprehensive Analysis Platform To Understand, Remedy, and Eliminate ALS (CAPTURE ALS)
Neuromuscular and Clinical Neurophysiology (EMG)
P6 - Poster Session 6 (12:00 PM-1:00 PM)
1-015

ALS drug discovery has been hampered by its complexity, clinical heterogeneity and rare disease status. Key advances will only be possible through multisite, multidisciplinary collaborations and the sharing of large amounts of data. CAPTURE ALS will leverage and expand the existing clinical network and infrastructure developed by the Canadian ALS NeuroImaging Consortium (CALSNIC) to provide the most comprehensive picture of a person living with ALS. Led by a group of basic and clinician scientists, it will be driven academically through four existing ALS centres of excellence in Edmonton, Toronto, Montreal, and Quebec.

The Comprehensive Analysis Platform To Understand, Remedy and Eliminate Amyotrophic Lateral Sclerosis (CAPTURE ALS) is an innovative initiative that will pool resources and talent in Canada to advance our understanding of the biological basis of ALS and address its heterogeneity.

CAPTURE ALS will provide the infrastructure and tools to enable the collection, storage, analysis and dissemination of standardized, longitudinal, multi-dimensional data and biosamples from ALS patients, related disorders, and healthy controls across Canada. Participants will be followed prospectively to longitudinally collect detailed clinical, neurocognitive, speech, electrophysiological and imaging data. Biospecimens, including serum, plasma, peripheral blood mononuclear cells (PBMCs), cerebrospinal fluid (CSF), and urine will be collected at the same intervals, with postmortem material collected when possible.

The rich datasets and samples collected through this platform will be used to develop and validate novel ALS biomarkers and enable the multidimensional stratification of ALS patients based on clinical phenotype, and imaging, genetic and cellular characteristics. Operating through Open Science principles, data and samples will be made rapidly available to investigators and industry partners.
CAPTURE ALS will contribute to global efforts to expedite ALS research, and provide hypothesis and data driven insights into disease mechanisms and clinical heterogeneity.
Authors/Disclosures
Sanjay Kalra, MD (University of Alberta)
PRESENTER
The institution of Dr. Kalra has received research support from Brain Canada Foundation. The institution of Dr. Kalra has received research support from Biogen.
Nicolas Dupre, MD, FAAN (CHU de Quebec - U Laval) Dr. Dupre has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Akcea Therapeutics Canada. The institution of Dr. Dupre has received research support from ARSACS Foundation. The institution of Dr. Dupre has received research support from CHUdeQuebec Foundation.
Angela L. Genge, MD (Mcgill University) Dr. Genge has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for AL-S Pharma. Dr. Genge has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Genge has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cytokinetics. Dr. Genge has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amylyx. Dr. Genge has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Quralis. Dr. Genge has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Genge has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MTPA. Dr. Genge has received personal compensation in the range of $0-$499 for serving as a Consultant for WAVE.
Janice Robertson Janice Robertson has nothing to disclose.
Christine Vande Velde Christine Vande Velde has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BridgeBio. Christine Vande Velde has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for MT Pharma. Christine Vande Velde has received research support from ALS Canada. Christine Vande Velde has received research support from Target ALS . Christine Vande Velde has received research support from Muscular Dystrophy Association. Christine Vande Velde has received research support from ALS Association.
Claire Magnussen No disclosure on file